Arenobufagin-loaded PEG-PLA nanoparticles for reducing toxicity and enhancing cancer therapy

Abstract

Arenobufagin (ArBu) is a natural anticancer drug with good anti-tumor effects, but its clinical applications and drug development potential are limited due to its toxicity. The purpose of this study is to reduce the toxic side effects of ArBu and improve the efficacy of tumor treatment by incorporating it into poly(ethylene glycol)-b-poly (lactide) co-polymer (PEG-PLA). ArBu@PEG-PLA micelles were prepared by a thin film hydration method. The optimized micelles were characterized by size, stability, drug loading, encapsulation rate, and drug release. The tumor-inhibition efficacy of the micelles was evaluated on A549 cells and tumor-bearing mice. The ArBu@PEG-PLA micelles have good drug-loading capacity, release performance, and stability. They can accumulate at the tumor site through the EPR effect. The micelles induce apoptosis through a mitochondrial apoptosis pathway. Compared with the free ArBu, the ArBu@PEG-PLA micelles had lower toxicity and higher safety in the acute toxicity evaluation experiment. The in vivo anti-tumor experiment with tumor-bearing mice showed that the tumor-inhibition rate of ArBu@PEG-PLA micelles was 72.9%, which was 1.28-fold higher than that of free ArBu (57.1%), thus showing a good tumor treatment effect. This study indicates that ArBu@PEG-PLA polymeric micelles can significantly improve the toxicity and therapeutic efficacy of ArBu. These can lead to a new therapeutic strategy to reduce the toxicity of ArBu and enhance tumor treatment.

Four Ounces Can Move a Thousand Pounds: The Enormous Value of Nanomaterials in Tumor Immunotherapy

“…In the field of biomedical science, polymer nanomaterials have become increasingly prevalent due to their high modifiability, biodegradability, and low cytotoxicity, making them highly suitable for medical applications such as tumor therapy, tissue engineering, regenerative medicine, drug delivery, and medical devices. [20,21] These polymeric nanomaterials used in medical applications are collectively referred to as medical polymeric nanomaterials. Specifically, this section intends to discuss the recent advancements in tumor immunotherapy utilizing organic polymer nanomaterials such as poly lactic-co-glycolic acid (PLGA), polyethyleneimine (PEI), polyethylene glycol (PEG), polycaprolactone (PCL), and polyglutamic acid (𝛾-PGA).…”

Investigation of morphologies and structures of Phloretin drug and PEG-b-PLA diblocks: A Dissipative particle dynamics simulations study

“…Yang et al synthesized ArBu-loaded PEG-PLA micelles (ArBu@PEG-PLA) via thin-film hydration. SEM analysis showed spherical nanoparticles sized 86-97 nm [33]. ArBu encapsulation efficiency ranged 80.3%-82.5%.…”

PLA-HA/Fe3O4 magnetic nanoparticles loaded with Curcumin: Physicochemical characterization and toxicity evaluation in HCT116 Colorectal cancer cells

“…They can reduce toxicity and increase the effectiveness of anticancer medications like arenobufagin (ArBu), tamoxifen, docetaxel, daunorubicin, and ibuprofen. [43] Exploring new avenues for targeted treatment and overcoming multidrug resistance, nanotechnologybased chemotherapy employing nanoparticles has opened up new possibilities. In vitro, cytotoxicity against breast cancer cells has been shown for polymeric nanoparticles of polylactic acid-poly (ethylene glycol) (PLA-PEG) copolymers encapsulating a novel biosurfactant.…”